Business
Kane Biotech Announces Publication of revyve® Wound Gel Article in the International Wound Journal
WINNIPEG, Manitoba, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE) (“Kane Biotech” or “Kane”) announces the publication of an article on its revyve® Antimicrobial wound gel in the International Wound Journal. The article “Wound Healing Property of a Novel Thermo-Reversible Wound Gel With Lasting Antimicrobial and Antibiofilm Activity” is first-authored by Dr. Jeyachchandran Visvalingam, Internal R&D Leader, and includes authors from the Miller School of Medicine, Dr. Phillip Fr
About this update from Kane Biotech Inc.
[{"type":"image","alt":"Kane Biotech Inc.","displaySize":"","headline":null,"caption":"Kane Biotech Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/8c0bc49cc705de4fa90f6da1d7452d9f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/r6.I5yq30fbtTHkzKWc_gQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8c0bc49cc705de4fa90f6da1d7452d9f","width":300,"height":100}},"lazy":false},{"type":"text","content":"WINNIPEG, Manitoba, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE) (“Kane Biotech” or “Kane”) announces the publication of an article on its revyve® Antimicrobial wound gel in the International Wound Journal. The article “Wound Healing Property of a Novel Thermo-Reversible Wound Gel With Lasting Antimicrobial and Antibiofilm Activity” is first-authored by Dr. Jeyachchandran Visvalingam, Internal R&D Leader, and includes authors from the Miller School of Medicine, Dr. Phillip Frost Department of Dermatology & Cutaneous Surgery, University of Miami.","length":579,"tagName":"p"},{"type":"text","content":"Key messages of the article as it relates to Kane’s revyve wound gel include:","length":77,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The thermo-reversible gel shifts from a low viscosity liquid to a form-fitting gel at body temperature, then re-liquefies when cooled for easy, atraumatic removal.","length":163,"tagName":"p"}]},{"val":[{"type":"text","content":"revyve demonstrated efficacy against a broad range of wound-related pathogens, including Staphylococcus aureus and Pseudomonas aeruginosa, with a 99.99%–99.9999% reduction in bacterial counts within 30 min.","length":206,"tagName":"p"}]},{"val":[{"type":"text","content":"There was sustained in vitro activity for up to 7 days, potentially reducing the number of dressing changes.","length":108,"tagName":"p"}]},{"val":[{"type":"text","content":"The safety and non-cytotoxicity of the gel were validated through biocompatibility testing and a porcine wound-healing study.","length":125,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":602,"olType":false},{"type":"image","alt":"US FDA 510(k) cleared and Health Canada approved revyve Antimicrobial Wound Gel","displaySize":"","headline":null,"caption":"...